Open an account

Biodesix

BDSX · NASDAQ

$23.87+$0.47 (+2.01%)TodayMarket closed ·
Prev close $23.40

About BDSX

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 334 full-time employees. The company went IPO on 2020-10-28. The company offers two tests (Nodify Lung tests) that assess the risk of cancer in lung nodules and three tests (IQLung tests) that provide treatment guidance after a lung cancer diagnosis. Nodify CDT and Nodify XL2 tests, marketed as Nodify Lung Nodule Risk Assessment, assess the lung nodule's risk of lung cancer to help identify the appropriate treatment pathway. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. The Nodify XL2 test is a blood-based proteomic test that evaluates the likelihood that a lung nodule is benign to help identify patients that may benefit from surveillance imaging. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests, marketed as part of its IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient’s immune system to help guide treatment decisions.

Employees
334
Headquarters
Louisville, Colorado
Listed
Oct 28, 2020
Sector
Health Care
Industry
Health Care Providers & Services
Website
biodesix.com

BDSX key statistics

Market cap
251.86M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
95.18K
Volume
49.38K
Open price
$23.50
High today
$24.92
Low today
$23.50
52 Week high
$31.35
52 Week low
$5.26

Biodesix (BDSX) at a glance

Biodesix (BDSX) last traded at $23.87, with a market cap of 251.86M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $23.50 and $24.92. The current price is 1.6% above the day's low and 4.2% below its high.

Volume so far is 49.38K shares, below the average of 95.18K shares a day.

Over the past year Biodesix has ranged from $5.26 to $31.35, and now sits 71% of the way up that range.

Biodesix met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.71 per share against an estimate of -$0.9203.

The average analyst price target is $37.54, 57.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $37.54
Low
$30.30
Now
$23.87
High
$43.05

BDSX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 22.2% on average.

  1. Q3 FY24: reported -$1.40 per share against an estimate of -$1.50
  2. Q4 FY24: reported -$1.20 per share against an estimate of -$1.36
  3. Q1 FY25: reported -$1.60 per share against an estimate of -$1.39
  4. Q2 FY25: reported -$1.60 per share against an estimate of -$1.39
  5. Q3 FY25: reported -$1.16 per share against an estimate of -$1.47
  6. Q4 FY25: reported -$0.49 per share against an estimate of -$0.8721
  7. Q1 FY26: reported -$0.81 per share against an estimate of -$1.12
  8. Q2 FY26: reported -$0.71 per share against an estimate of -$0.9203

BDSX news

  • Press releaseGlobe Newswire

    Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

  • Press releaseGlobe Newswire

    Biodesix to Participate in Upcoming Investor Conferences

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseGlobe Newswire

    Biodesix to Participate in Upcoming Investor Conferences

  • Market-Moving News for January 12th

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Rishabh Mishra

    Stock Market Today: Dow Futures Slip, Nasdaq Rises As Trump Files Tariff Appeal—American Eagle, Salesforce, Lululemon In Focus (UPDATED)

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

Similar companies

Companies in the same industry as Biodesix

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.